-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CVD-1208S122 in Bacillary Dysentery (Shigellosis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CVD-1208S122 in Bacillary Dysentery (Shigellosis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.CVD-1208S122 in Bacillary Dysentery (Shigellosis) Drug Details: CVD-1208S122 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dapagliflozin Propanediol in Diastolic Heart Failure (HFpEF)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Dapagliflozin Propanediol in Diastolic Heart Failure (HFpEF) Drug Details: Dapagliflozin (Forxiga, Edistride, Gledepa, Duforzig, Kedgeo,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AD-214 in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AD-214 in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AD-214 in Idiopathic Pulmonary Fibrosis Drug Details: AD-214 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AD-214 in Chronic Kidney Disease (Chronic Renal Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AD-214 in Chronic Kidney Disease (Chronic Renal Failure) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AD-214 in Chronic Kidney Disease (Chronic Renal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dapagliflozin Propanediol in Portal Hypertension
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Dapagliflozin Propanediol in Portal Hypertension Drug Details: Dapagliflozin (Forxiga, Edistride, Gledepa, Duforzig, Kedgeo, Tapleo) belongs...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FB-704A in Chronic Kidney Disease (Chronic Renal Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FB-704A in Chronic Kidney Disease (Chronic Renal Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FB-704A in Chronic Kidney Disease (Chronic Renal Failure)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FB-704A in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FB-704A in Rheumatoid Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FB-704A in Rheumatoid Arthritis Drug Details: FB-704A is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cannabidiol 1 in Pericarditis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cannabidiol 1 in Pericarditis Drug Details: Cannabidiol is under development for the treatment of diastolic heart...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cannabidiol 1 in Myocarditis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cannabidiol 1 in Myocarditis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Cannabidiol 1 in MyocarditisDrug Details:Cannabidiol is under development for the treatment of diastolic heart...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Evolocumab in Hypercholesterolemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Evolocumab in Hypercholesterolemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Evolocumab in HypercholesterolemiaDrug Details: Evolocumab (AMG-145, Repatha) is a monoclonal antibody acts as lipid...